Dawson James Securities Announces the Completion of $5.2 Million Underwritten Offering for Tonix Pharmaceuticals

BOCA RATON, FL / ACCESSWIRE / October 31, 2016 / Dawson James Securities, Inc. in conjunction with Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced the closing on October 31st of an underwritten public offering of 9,500,000 units, consisting of 9,500,000 shares of common, and warrants to purchase an aggregate of 4,750,000 shares of common stock, at an offering price of $0.55 per unit. Dawson James also purchased additional warrants to acquire 712,500 common shares pursuant to the over-allotment option exercised in part by Dawson James. The warrants have an exercise price of $0.63 per share and are exercisable for a period of five years. The units were sold at the public offering price of $0.55 per unit, bringing the aggregate gross proceeds from the offering to $5.2 million, before deducting underwriting discounts and commissions and other offering expenses.

Dawson James Securities, Inc. acted as the sole book-running manager for the offering.

“We are pleased to provide the capital necessary for the Company to support the continued development and phase 3 studies of TNX-102 SL for the treatment of posttraumatic stress disorder (PTSD),” said Robert D. Keyser, Dawson James CEO. Tonix intends to utilize the net proceeds of the offering for general working capital and to further develop other pipeline programs.

The shares described above were offered by Tonix pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”). A final prospectus supplement relating to the offering was filed with the SEC and is available, along with the accompanying base prospectus, on the SEC’s website at http://www.sec.gov, or by contacting Dawson James: 1 N. Federal Hwy; Suite 500, Boca Raton, FL 33432 ATTN: Prospectus Department.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Tonix Pharmaceuticals Holding Corp.

Tonix is developing next-generation medicines for common disorders of the central nervous system, with its lead program focusing on posttraumatic stress disorder. This disorder is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. This press release and further information about Tonix can be found at www.tonixpharma.com.

About Dawson James Securities

Dawson James Securities specializes in capital raising for small and microcap public and private growth companies primarily in the Life Science/Health Care, Technology and Consumer sectors and is a full service investment banking firm with research, institutional and retail sales, and execution trading and corporate services. Headquartered in Boca Raton, FL, Dawson James is privately held with offices in New York, California, Maryland and New Jersey and North Carolina. www.dawsonjames.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes”, “expects”, “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Member FINRA/SIPC.

For more information, please contact:

Elise Stern, Managing Director, Head of Capital Markets
estern@dawsonjames.com
561-208-2926

SOURCE: Dawson James Securities, Inc.

ReleaseID: 448007